GFAP
Glial Fibrillary Acidic Protein (Serum / CSF Astrocyte Biomarker)
グリア線維性酸性タンパク質（血漿・血清 GFAP：アストロサイト活性化マーカー）
1. Biological & Technical Mechanism
Glial Fibrillary Acidic Protein (GFAP) is the principal intermediate filament cytoskeleton protein expressed by mature astrocytes in the CNS. Upon neuroinflammation, chronic microglial-astrocytic crosstalk, or blood-brain barrier remodeling, astrocytes upregulate and release soluble GFAP fragments into CSF and blood, quantifiable via ultrasensitive Simoa assays. In Multiple Sclerosis, serum GFAP behaves distinctly from serum Neurofilament Light Chain (NfL): while NfL spikes transiently during acute focal relapses and gadolinium-enhancing lesions, serum GFAP remains stably elevated in patients with chronic active lesions and strongly predicts future Progression Independent of Relapse Activity (PIRA) and gray matter atrophy.
GFAP（Glial Fibrillary Acidic Protein）は中枢神経系のアストロサイトに特異的に発現する主要中間径フィラメントタンパク質です。慢性神経炎症やアストログリオーシスが生じると、髄液および末梢血中のGFAP濃度が上昇します。多発性硬化症（MS）研究において、血清NfLが「急性の局所再発やガドリニウム造影病変に伴う軸索破壊」を反映して一過性に上昇するのに対し、血清GFAPは「慢性活動性病変におけるアストロサイト・ミクログリア活性化とPIRA（再発に依存しない進行）」を特異的に反映することが明らかになり、NfLとGFAPの2軸による患者層別化が確立されています。また、アルツハイマー病においてもアミロイドβ蓄積初期のアストロサイト反応を捉える血液バイオマーカーとして重要です。
2. Open Science & Clinical Trial Significance
Dual biomarker profiling ('High GFAP / Low NfL' vs. 'High NfL') is standard across modern MS cohorts (Swiss MS Cohort, MSBase) and Alzheimer's plasma panels.
「高GFAP・低NfL」群は抗CD20抗体等で急性再発を抑えていてもPIRAによるEDSS悪化リスクが高い群として同定されるため、進行型MSの臨床試験やマルチモーダル公開コホート解析における必須共変量となっています。
Related Neuroscience Terms & Standards
Axonal cytoskeletal protein released into CSF and blood upon neuroaxonal injury; a cross-disease biomarker of neurodegeneration rate in ALS, MS, AD, and FTD.
Irreversible accumulation of neurological disability occurring outside of clinical relapses, driven by diffuse smoldering neuroinflammation, chronic active lesions, and neuroaxonal loss in MS.
Chronic white matter MS lesions bordered by a dense rim of iron-laden, proinflammatory activated microglia/macrophages, visible on T2* phase MRI, SWI, and QSM.
Standard 0.0–10.0 ordinal clinical rating scale quantifying neurological disability across 8 functional systems and ambulation capacity in Multiple Sclerosis.
Highly sensitive fluid biomarker reflecting both cerebral amyloid-beta plaque burden and early tau tangle phosphorylation in Alzheimer's disease.
Open Datasets & Research Publications Related to GFAP
GFAP as a Biomarker of Stroke Subtype and Brain Tissue Damage in Acute Stroke: A Systematic Review and Meta-Analysis
BackgroundGlial fibrillary acidic protein (GFAP) is a promising blood biomarker that can distinguish intracerebral hemorrhage (ICH) from acute ischemic stroke (AIS). We aimed to summarize the existing evidence regarding: 1) the diagnostic accuracy of GFAP to differentiate ICH from AIS, and from undi...
Serial neoGFAP outperforms total GFAP for monitoring and 6-month outcome discrimination after moderate to severe traumatic brain injury: an exploratory single-site cohort study
BackgroundSerial glial fibrillary acidic protein (GFAP) trajectories have become an important framework for contextualizing evolving secondary-injury pathophysiology after moderate-to-severe traumatic brain injury (msTBI). However, total GFAP pools release and clearance signals that may be less usef...
MSDA: COVID19 GDSI LocalDashboard - Federated MS Data Toolkit
Official open-source repository and tool for Multiple Sclerosis federated research and data harmonization under MS-DATA-ALLIANCE.
Global Data Sharing Initiative (GDSI): Containerized Federated Analysis Pipeline for MS Registries
International federated research initiative and containerized query framework allowing participating national MS registries to analyze disease-modifying therapy (DMT) safety, anti-CD20 outcomes, and PIRA progression without transferring identifiable patient data.
CNM-Au8 Treatment Is Associated With Reduced Chronic Lesion Tissue Expansion in Relapsing-Remitting Multiple Sclerosis
BackgroundCNM-Au8, a catalytic nanocrystalline gold suspension, is proposed to support neuronal bioenergetics, but its effect on chronic lesion evolution in multiple sclerosis (MS) has not been reported. ObjectivesTo evaluate the effect of CNM-Au8 on chronic lesion tissue expansion (CLTE). Results...
Dietary Patterns and Nutritional Factors in Multiple Sclerosis: A Narrative Review
Research article from Europe PMC.
Disclaimer: This encyclopedia entry is intended for academic neuroscience research and data science reference only, and does not constitute medical advice.